January 8, 2013

Richmond woman in drug suit

Kennebec Journal Staff

About DES

DES (diethylstilbestrol) was the first synthetic form of estrogen.

It was prescribed from 1938 to 1971 to prevent miscarriages and other pregnancy complications, though it was found to be ineffective in the 1950s.

Women exposed in the womb have an increased risk of reproductive problems and certain cancers and pre-cancerous conditions. Men have a greater risk of noncancerous cysts and genital abnormalities but no greater risk for infertility.

There is no medical test to determine whether a person was exposed to DES. If you know or suspect that your mother took DES, talk to your doctor about health screenings and precautions necessary to protect your health.

Source: National Institutes of Health

BY KELLEY BOUCHARD

Portland Press Herald

A Richmond woman is among more than 100 plaintiffs awaiting the outcome of a Boston federal court trial, set to start Tuesday, that was initiated by women who've had breast cancer and whose mothers used the synthetic hormone DES while pregnant.

The lawsuit claims that Eli Lilly and Co. was negligent in its failure to test for and warn against problems related to DES, or diethylstilbestrol, which has been found to increase fertility problems and cancer risks in daughters of women who used the drug.

The landmark court case involves four sisters from Pennsylvania, but the outcome is expected to affect all other claims related to a class-action lawsuit filed two years ago, including a complaint by Patricia Royall, of Richmond.

Royall's mother, Virginia Inness-Brown Conn, was one of millions of pregnant women in the United States who were prescribed DES between 1938 and 1971 to prevent miscarriages and premature births.

Royall was 28 when she learned that she's a so-called DES daughter. A bout of profuse vaginal bleeding sent her to the emergency room. The doctor noticed reproductive abnormalities and asked if her mother had taken DES. She had no idea.

"I asked my mother and she was a little bit defensive at first," said Royall, now 59. "Then she told me she took DES the whole time she was pregnant with me because she had a miscarriage."

In the years since learning she's a DES daughter, Royall has had a host of health problems, including breast and cervical cancer, an autoimmune disease and a pre-cancerous growth in her colon.

Her reproductive abnormalities included a hooded cervix and a tilted uterus, both of which contributed to a miscarriage and the premature birth of her son. Her mother, who was 84 when she died in 2011, also had breast cancer.

The oldest of five children, Royall said none of her siblings -- three sisters and a brother -- has had cancer or any other serious illness. Royall said her mother didn't take DES while pregnant for them.

Royall and the other DES plaintiffs are being represented by Aaron Levine & Associates, a Washington, D.C. law firm, in claims against Eli Lilly and 13 other drug companies.

The firm claims that Eli Lilly and other drug makers never conducted controlled testing and ignored studies published as early as the 1930s that found DES increased the risk of cancer and developmental problems, according to a news release.

The drug companies have argued that no firm link has been established between DES and breast cancer, the Associated Press reported.

Eli Lilly said Monday in a prepared statement that the claims are without merit and the company is "prepared to defend against them vigorously."

The case now in Boston federal court is considered a bellwether trial, scheduled because judge-ordered mediation failed to produce settlements, the AP reported.

The outcome of the trial is expected to influence actions of both the DES daughters and the drug companies and could lead to settlements for all of the plaintiffs.

(Continued on page 2)

Were you interviewed for this story? If so, please fill out our accuracy form

Send question/comment to the editors




Further Discussion

Here at KJonline.com we value our readers and are committed to growing our community by encouraging you to add to the discussion. To ensure conscientious dialogue we have implemented a strict no-bullying policy. To participate, you must follow our Terms of Use.

Questions about the article? Add them below and we’ll try to answer them or do a follow-up post as soon as we can. Technical problems? Email them to us with an exact description of the problem. Make sure to include:
  • Type of computer or mobile device your are using
  • Exact operating system and browser you are viewing the site on (TIP: You can easily determine your operating system here.)